CAS: 132682-98-5; Glufosfamide,B-D-Glucopyranose,1-(N,N-Bis(2-Chloroethyl)Phosphorodiamidate)-

该化合物是一种合成化合物,主要用于医药化学领域,特别是作为抗菌剂;它是硫化烷基剂Ifosfamide的衍生物,旨在提高其治疗效力,同时有可能降低毒性;glufosfamid的化学结构包括氯乙基侧链,这是其行动机制的关键,允许其形成DNA交叉链和抑制癌症细胞扩散;该化合物的特点是其溶性在水和有机溶剂中的溶性,便于其配制临床用途;Glufosfamid因其对包括固态肿瘤在内的各种癌症的有效性而受到调查,并经常与其他乳房化剂一起研究,以改善治疗结果;其药性皮质反应,包括吸收,分布,新陈代谢和排泄,对于了解其治疗窗口和潜在副作用至关重要;与许多止痛剂一样,对病人进行仔细监测对于管理不利影响和优化治疗疗程十分必要.

结构式图片

合成工艺路线路线简述

    📜[(2R,3R,4S,5R,6S)-3,4,5-Triacetyloxy-6-Bis(2-Chloroethylamino)Phosphoryloxyoxan-2-Yl]Methyl Acetate置于sodium Methylate 甲醇体系中,化学反应 0.5H,以89%的收率获得葡磷酰胺
    参考文献:Wo2008/11588
    标题:Wo2008/11588

    海关参考信息

    专利信息


    专利号:WO-2017100796-A1
    优先权日:2015-12-11
    标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
    发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
    权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
    摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

    专利号:US-2017283878-A1
    优先权日:2015-12-11
    标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
    发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
    权利人:ACADEMIA SINICA
    摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

    专利号:US-8598153-B2
    优先权日:2006-09-22
    标题 :Method of treatment using fatty acid synthesis inhibitors
    发明人:SINGH SHEO B; TOTA MICHAEL R; WANG JUN
    权利人:SINGH SHEO B; TOTA MICHAEL R; WANG JUN; MERCK SHARP & DOHME
    摘要:The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.

    专利号:US-10272065-B2
    优先权日:2013-01-14
    标题 :Gem-difluorinated C-glycoside compounds as anti-cancer agents
    发明人:SLILATY STEVE N
    权利人:ADVANOMICS CORP; BENOIT & COTE
    摘要:The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines.

    专利号:US-9585890-B2
    优先权日:2012-09-26
    标题 :Modulators of androgen synthesis
    发明人:DILLY SUZANNE; STOLOFF GREGORY; TAYLOR PAUL
    权利人:TANGENT REPROFILING LTD
    摘要:The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.

    专利号:US-9808462-B2
    优先权日:2012-09-26
    标题 :Modulators of androgen synthesis
    发明人:DILLY SUZANNE; STOLOFF GREGORY; TAYLOR PAUL
    权利人:TANGENT REPROFILING LTD
    摘要:The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Lacombe D. Glufosfamide: can we improve the process of anticancer agent development? Expert Opin Investig Drugs. 2012 May;21(5):749-54. doi: 10.1517/13543784.2012.670218. Epub 2012 Mar 16. Review. doi: 10.1097/CAD.0b013e328345e1e0. Review. doi: 10.1097/COC.0b013e3181979204. doi: 10.1016/j.ejphar.2009.06.024. Epub 2009 Jun 21. doi: 10.1007/s00280-009-1028-3. doi: 10.1016/j.ejca.2008.12.022. Epub 2009 Jan 31.
    8: Chiorean EG, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, Colowick AB, Tidmarsh GF, Loehrer PJ. A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2008 May;61(6):1019-26. Epub 2007 Jul 28. Chinese. German. Epub 2006 Feb 7. Review. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur J Cancer. 2004 Mar;40(5):667-72. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol. 2003 Dec;14(12):1732-4. Review.

    合成参考文献


    摘要:
    摘要:
    摘要:
    摘要:
    摘要:Bronstein, A.C., P.L. Currance; Emergency Care for Hazardous Materials Exposure. 2nd ed. St. Louis, MO. Mosby Lifeline. 1994., p. 139
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知